Literature DB >> 3492226

Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.

L V Rao, S I Rapaport.   

Abstract

We have extended earlier studies (Blood 66:204, 1985) of a mechanism of inhibition of factor VIIa/tissue factor activity that requires a plasma component (called herein extrinsic pathway inhibitor or EPI) and factor Xa. An activated peptide release assay using 3H-factor IX as a substrate was used to evaluate inhibition. Increasing the tissue factor concentration from 20% to 40% (vol/vol) overcame the inhibitory mechanism in normal plasma but not in factor VII-deficient plasma supplemented with a low concentration of factor VII. A second wave of factor IX activation obtained by a second addition of tissue factor to plasma with a normal factor VII concentration was almost abolished by supplementing the reaction mixture with additional EPI and factor X. Factor Xa's active site was necessary for factor Xa's contribution to inhibition, but preliminary incubation of factor Xa with EPI in the absence of factor VIIa/tissue factor complex or of factor VIIa/tissue factor complex in the absence of EPI did not replace the need for the simultaneous presence of factor Xa, factor VIIa/tissue factor, calcium, and EPI in an inhibitory reaction mixture. Inhibition of factor VIIa/tissue factor was reversible; both tissue factor and factor VIIa activity could be recovered from a dissociated, inhibited factor VIIa/tissue factor complex. EPI appeared to bind to a factor VIIa/tissue factor complex formed in the presence of factor Xa but not to a factor VIIa/tissue factor complex formed in the absence of factor Xa.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492226

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Expression and characterization of wild-type TFPI and the [P151L]TFPI mutant in insect cells.

Authors:  Elmar Thyzel; Sabine Siegling; Thomas Brinkmann; Knut Kleesiek; Christian Götting
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Authors:  T J Girard; K Grunz; N M Lasky; J P Malone; G J Broze
Journal:  J Thromb Haemost       Date:  2018-10-22       Impact factor: 5.824

Review 4.  New biological concepts on coagulation inhibitors.

Authors:  N Sala; J Fontcuberta; M L Rutllant
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  Protease nexin-2/amyloid beta-protein precursor: a cerebral anticoagulant?

Authors:  D D Cunningham
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Why does the blood not coagulate?

Authors:  O D Ratnoff
Journal:  West J Med       Date:  1993-02

Review 7.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 8.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

9.  Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.

Authors:  P M Sandset; B J Warn-Cramer; L V Rao; S L Maki; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

10.  Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor.

Authors:  J Kleniewski; V H Donaldson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.